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Objectives To determine the proportion of pediatric randomized con-
trolled trials (RCTs) that are prematurely discontinued, examine the reasons
for discontinuation, and compare the risk for recruitment failure in pedi-
atric and adult RCTs.
Study design A retrospective cohort study of RCTs approved by 1 of
6 Research Ethics Committees (RECs) in Switzerland, Germany, and
Canada between 2000 and 2003. We recorded trial characteristics, trial
discontinuation, and reasons for discontinuation from protocols, corre-
sponding publications, REC files, and a survey of trialists.
Results We included 894 RCTs, of which 86 enrolled children and 808
enrolled adults. Forty percent of the pediatric RCTs and 29% of the adult
RCTs were discontinued. Slow recruitment accounted for 56% of pediat-
ric RCT discontinuations and 43% of adult RCT discontinuations. Multi-
variable logistic regression analyses suggested that pediatric RCT was
not an independent risk factor for recruitment failure after adjustment for
other potential risk factors (aOR, 1.22; 95% CI, 0.57-2.63). Independent
risk factors were acute care setting (aOR, 4.00; 95% CI, 1.72-9.31),
nonindustry sponsorship (aOR, 4.45; 95% CI, 2.59-7.65), and smaller
planned sample size (aOR, 1.05; 95% CI 1.01-1.09, in decrements of 100
participants).
Conclusion Forty percent of pediatric RCTs were discontinued
prematurely, owing predominately to slow recruitment. Enrollment of
children was not an independent risk factor for recruitment failure. (J
Pediatr 2017;184:209-14).
RCT Randomized controlled trial
REC Research Ethics Committee
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Randomized controlled trials (RCTs) involving chil-dren are rare compared with trials of adults,1-5 owingin part to lack of funding.4,6 In addition, pediatric trials
may be at particularly high risk for premature trial discon-
tinuation, for several reasons. First, recruitment of children in-
volves specific challenges;7-9 the informed consent process is
more complex7 and may be affected by the reservations and
skepticism of parents (who usually must provide consent for
their children) or pediatricians.10-15 Second, compared with adult
trials, rules for stopping a pediatric trial for benefit, harm, or
futility may be stricter, further increasing the risk for early
discontinuation.
On the other hand, a report of the United Kingdom Chil-
dren’s Cancer Study Group has suggested that pediatric trials
recruit more successfully than adult trials,16 possibly owing to
the nation’s highly collaborative network of pediatric oncol-
ogy centers.17 Other qualitative studies have found that parents
are less skeptical about having their child participate in clini-
cal trials than was anticipated.14,18 Therefore, recruitment failure
may be no higher—or perhaps even lower—for pediatric trials
compared with adult trials.
Little empirical data exist about the actual risk of prema-
ture trial discontinuation in pediatrics. In a survey of 110 pub-
lished pediatric RCTs, 32 were discontinued overall, including
8 for slow recruitment, 7 for futility, 6 for efficacy, 6 for harm,
and 5 for other reasons.19,20 Another survey of cardiovascular
studies registered at ClinicalTrials.gov suggested that 65 of 782
pediatric studies (8%) were discontinued prematurely. However,
the foregoing data originate from published or registered trials
and might not be representative of all initiated trials; many dis-
continued trials remain unpublished21 or fail to acknowledge
discontinuation in trial registries.22
We analyzed an international cohort of RCTs approved by
6 Research Ethics Committees (RECs) in 3 countries to de-
termine the risk of trial discontinuation in pediatric trials and
to compare the risk for trial discontinuation specifically due
to slow recruitment between pediatric and adult trials.
Methods
Previous publications have described the rationale and design
of this international cohort study,21,23 and we have presented
parts of the regression analysis previously in the context of acute
care RCTs.24 In brief, we included RCTs approved between 2000
and 2003 by 6 RECs in Switzerland (Basel, Lucerne, Zurich,
and Lausanne), Germany (Freiburg), and Canada (Hamil-
ton). Each REC was responsible for human research in large
university centers and hospitals in its respective catchment area.
Every REC had pediatric units in its catchment area and ap-
proved pediatric trials. We approached the RECs through ex-
isting contacts and, to minimize the number of ongoing or
unpublished RCTs, focused on protocols that had been ap-
proved more than 10 years earlier.
For this analysis, we excluded protocols of RCTs that in-
volved only healthy volunteers, were never initiated, or were
reported as ongoing as of April 2013 (Figure). The partici-
pating RECs either approved the study or explicitly stated that
no formal ethical approval was necessary.
Definitions
We classified an RCT as pediatric if more than 50% of the en-
rolled patients were younger than 18 years of age. The ratio-
nale for this inclusive threshold was that trials with more than
50% children are likely to be affected by pediatric-specific
challenges.
We considered an RCT discontinued if the investigators in-
dicated trial discontinuation in correspondence with an REC,
in a journal publication, or in their response to our survey (see
below). If still unclear, we compared the final sample size with
the planned sample size. We classified a trial as discontinued
if the final sample size was ≤90% of the planned sample size.23
If the planned or final sample size was unclear, we classified
the trial status as unclear. In addition, we recorded reasons for
trial discontinuation.
ExcludedAssessed for eligibility
3819 REC protocols screened 2419 no RCT
931 Basel, 917 Freiburg, 981 
Hamilton, 692 Lausanne, 135 
Lucerne, 160 Zürich
328 protocol duplicates
87 no complete protocol available
41 not approved
123 RCTs enrolling healthy volunteers
53 RCTs never started (including 4 pediatric RCTs)
1080 approved RCT protocols
289 Basel, 418 Freiburg, 198 
10 RCTs still on-going (including 1 pediatric RCT)Hamilton, 192 Lausanne, 38 
Lucerne, 54 Zürich
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Data Sources and Abstraction
Reviewers trained in trial methodology abstracted 30% of RCT
protocols independently and in duplicate using pretested forms
with detailed written instructions, and following formal cali-
bration exercises with all data abstractors. Disagreements arising
in duplicate review were resolved by discussion. Single inves-
tigators abstracted the remaining RCT protocols, with peri-
odic duplicate agreement checks from a random sample of
protocols at several points during the process.
We followed up on the completion status and publication
history of the RCTs as of April 27, 2013, using information from
REC files and conducting comprehensive searches for corre-
sponding publications in electronic databases and trial
registries.23 If trial completion or publication status re-
mained unclear, we surveyed the investigator by sending a stan-
dardized questionnaire through the overseeing REC. We
extracted data from all corresponding publications indepen-
dently and in duplicate and resolved disagreements by con-
sensus or third-party adjudication.
Statistical Analyses
We present trial characteristics, discontinuation, and publi-
cation status as frequencies and percentages stratified by
pediatric/adult. To determine the prevalence of pediatric trials
in the overall cohort, we excluded RCTs that were approved
in Zurich, where we had selective access to pediatric and sur-
gical trials only. To determine the proportion of discontin-
ued pediatric trials, we considered RCTs from all centers and
excluded RCTs with unclear completion status, assuming that
these RCTs were missing at random.
We used complete-case multivariable logistic regression
analysis to investigate the association between enrollment of
pediatric vs adult patients (independent variable) and trial dis-
continuation due to slow recruitment.23 We limited our re-
gression analysis to trials that were either completed or
discontinued due to slow recruitment. We also excluded pilot
trials (4 pediatric, 47 adult) and cluster trials (2 pediatric, 6
adult) for which we expected different recruitment mecha-
nisms. Independent variables were pediatric (vs adult) pa-
tients, investigator sponsorship (vs industry), sample size (as
planned, continuous variable), multicenter (vs single-center),
cross-over design (vs parallel), active control (vs placebo or non-
active intervention), reported method to predict recruitment
rate (vs no method reported), logistical support from a con-
tract research organization or clinical trial unit (vs no support
reported), and acute care (including emergency and inten-
sive care vs nonacute care). The study protocol provides ra-
tionales for the chosen variables.23 The event-to-variable ratio
was 10 (90 trials discontinued due to slow recruitment and 9
explanatory variables). We conducted sensitivity analyses using
multiple imputations for missing information about trial
discontinuation.15 A 2-tailed P value ≤.05 was considered to
indicate statistical significance.
Motivated by reports that pediatric oncology RCTs may be
at lower risk for early stopping compared with adult RCTs,16,17,25
we further explored whether pediatric oncology RCTs dif-
fered from other pediatric RCTs in terms of their rate of pre-
mature discontinuation. For this analysis, we did not adjust
for other potential risk factors owing to the limited power.
Results
Classification and Prevalence of Pediatric Trials
We included 894 RCTs, of which we classified 86 (10%) as pe-
diatric RCTs and 808 (90%) as adult RCTs (Figure). Thirty-
three trials included a mixed-age population, of which we
classified 9 as pediatric because the proportion of children
younger than 18 years was >50%. All 9 trials focused on con-
ditions that typically manifest in childhood (ie, 4 on pediat-
ric tumors, 2 on cerebral palsy, 2 on cystic fibrosis, 1 on type
1 diabetes). After excluding the 43 trials approved in Zürich,
the proportion of pediatric trials in the remaining 5 RECs was
6% (53 of 851) (Table I; available at www.jpeds.com).
Trial Characteristics
Most of the pediatric RCTs were multicenter, investigator-
initiated trials and enrolled children of various age groups
(Table II). Compared with the adult trials, pediatric trials were
more frequently conducted in the acute care setting (15% vs
6%), were less frequently sponsored by industry (44% vs 63%),
and more frequently piloted their informed consent process
(7% vs 1%).
Trial Discontinuation
We determined trial discontinuation from the publication alone
(61 of 249; 25%), the survey alone (69 of 249; 28%; response
rate, 80%), REC files alone (67 of 249; 27%), combined sources
(27 of 249; 11%), or recruiting <90% of the target sample (25
of 249; 10%; including 5 pediatric trials).23 Of the 894 in-
cluded RCTs, 575 (64%) were completed, 249 (28%) were dis-
continued before enrollment of target sample size, and
completion status was unclear for 70 RCTs (8%) (Table III).
Of the 80 pediatric RCTs with known status, 32 (40%) were
discontinued. Of the 744 adult RCTs with known recruit-
ment status, 217 (29%) were discontinued. Slow recruitment
was the most frequent reason for discontinuation in both the
pediatric (15 of 27; 56%) and adult (85 of 197; 43%) RCTs
(Table III). The difference was significant in the unadjusted
logistic regression model (OR, 1.95; 95% CI, 1.00-3.81), but
not after adjustment for other potential risk factors (OR, 1.22;
95% CI, 0.57-2.63). Independent risk factors for trial discon-
tinuation due to slow recruitment were investigator
(nonindustry) sponsorship (aOR, 4.45; 95% CI, 2.59-7.65),
acute care setting (aOR, 4.00; 95% CI, 1.72-9.31), and smaller
planned sample size (aOR, 1.05; 95% CI, 1.01-1.09, in decre-
ments of 100) (Table IV). The results were robust to sensitiv-
ity analyses using multiple imputations for missing data.24
None of 9 pediatric cancer trials was discontinued due to
slow recruitment (Table V; available at www.jpeds.com).
Trial Publication and Reporting of Discontinuation
After a median follow-up of 11.6 years from REC approval,
46 of the 86 pediatric trials (53%) were published as a
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peer-reviewed journal article (14 in pediatric journals, 23 in
other specialty journals, and 9 in general medical or surgical
journals), and another 8 (9%) were published as abstracts only.
We could not identify any publications corresponding to the
remaining 32 (37%) REC-approved trial protocols. The re-
spective proportions in the 808 adult RCTs were 484 (60%)
published in a peer-reviewed journal, 48 (6%) published as ab-
stracts, and 276 (34%) not published (Table VI; available at
www.jpeds.com).
Of the 32 discontinued pediatric trials, 12 (38%) were pub-
lished as a peer-reviewed journal article, of which 5 explicitly
reported that the trial had stopped early.
Discussion
In an international cohort of 894 RCTs, 86 enrolled 50% or
more children. Of these, 40% were discontinued prema-
turely. The main reason for trial discontinuation was slow re-
cruitment. Overall, the risk for discontinuation due to slow
recruitment was higher in pediatric RCTs than in adult RCTs;
however, multivariable logistic regression analysis suggested that
the pediatric setting is not an independent risk factor. Instead,
an elevated risk for discontinuation due to slow recruitment
was associated with investigator sponsorship (nonindustry),
acute care setting (eg, newborn intensive care), and smaller
planned sample size of RCTs.
Strengths of our study include collaboration with 6 RECs
from 3 countries to document the history of 894 RCTs that
received REC approval during a 3-year period. We had full
access to all REC files and successfully contacted 80% of the
authors to clarify whether their trial was stopped early and if
so, why. We involved trained methodologists to identify eli-
gible studies and to collect data. To minimize associations due
to chance alone, we considered only a limited number of vari-
ables in our statistical model and conducted sensitivity analy-
ses using multiple imputations for missing data.
Our study is limited by the reporting quality of the origi-
nal RCT protocols and reports, which did not always report
information regarding trial discontinuation. We used single data
extraction for almost 70% of the protocols, thereby poten-
tially increasing extraction errors; however, we used prepiloted
extraction forms with detailed written instructions, con-
ducted formal calibration exercises with all data extractors, and
checked extractions from a random sample of protocols at
several points during the process. Agreement was excellent, with
only 2 discrepancies in answers to 30 main questions of the
extraction form among 270 protocols extracted in duplicate.
In addition, a second investigator verified all outcome data on
discontinuation and publication of RCTs.
Our findings are based on protocols that were approved more
than 10 years ago. Data from more recently initiated trials are
not available but might differ. Advances in standards for RCT
planning26 and understanding of the recruitment process27
might help reduce the high proportion of discontinued






Age group, n (%)
Unborn/preterm/newborn (0 y) 15 (17)
Infant/toddler (eg, 0-3 y) 10 (12)
Primary school (eg, 4-11 y) 2 (2)
Adolescent (eg, 12-17 y) 8 (9)
Mix, primary school/adolescent (eg, 6-17 y) 12 (14)
Broad mix (eg, 1-21 years) 39 (45)
Research ethics committee, n (%)
Basel 5 (6) 216 (27)
Hamilton 15 (17) 163 (20)
Freiburg 23 (27) 249 (31)
Lausanne 5 (6) 144 (18)
Zürich* 33 (38) 10 (1)
Lucerne 5 (6) 26 (3)
Acute care (emergency or intensive care),
n (%)
13 (15) 51 (6)
Oncology, n (%) 10 (12) 171 (21)
Industry sponsorship, n (%) 38 (44) 513 (63)
Drug intervention (in 1 or more arms), n (%) 70 (81) 676 (84)
Planned target sample size, median (IQR) 200 (80-447) 275 (103-630)
Planned centers, n (%)
Multiple 67 (78) 674 (83)
Single 18 (21) 131 (16)
Unclear 1 (1) 3 (0)
Unit of randomization, n (%)
Individuals 84 (98) 795 (98)
Clusters 2 (2) 10 (1)
Body parts 0 (0) 30 (4)
Study design, n (%)
Parallel 81 (94) 755 (93)
Cross-over 4 (5) 37 (5)
Factorial 1 (1) 14 (2)
Unclear 0 (0) 2 (0)
Study purpose, n (%)
Superiority 57 (66) 595 (74)
Noninferiority 19 (22) 120 (15)
Unclear 10 (12) 93 (12)
Labeled as pilot RCT, n (%) 5 (6) 64 (8)
Comparison group(s), n (%)
Included placebo or no treatment (often
add-on RCTs)
50 (58) 483 (60)
Active comparator(s) only 36 (42) 325 (40)
Data Safety and Monitoring Board mentioned,
n (%)
18 (21) 239 (30)
Method for predicting recruitment rate
mentioned, n (%)
21 (24) 60 (7)
Pilot study including informed consent, n (%) 6 (7) 5 (1)
Reported methodological/logistical support,
n (%)
31 (36) 355 (44)
*In Zurich, we selectively included pediatric and surgical trials only.
Table III. Prevalence of trial discontinuation and re-





Completion status, n (%)
Completed 48 (56) 527 (65)
Discontinued 32 (37) 217 (27)
Unclear 6 (7) 64 (8)
Reason for discontinuation, n (%)
Slow recruitment 15 (19) 85 (11)
Futility 4 (5) 33 (4)
Benefit/harm 5 (6) 28 (4)
Other* 3 (3) 51 (6)
Unknown reason 5 (6) 20 (2)
*Such as administrative, strategic, or financial.
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pediatric trials. It is unlikely that the main risk factors for re-
cruitment failure have changed substantially over time, however.
Although our collaboration with 6 RECs in 3 countries in-
creases the generalizability of our results, our findings may not
be transferable to RCTs performed in other jurisdictions, such
as in developing countries, where unique trial completion chal-
lenges exist.
A previous analysis of reasons for discontinuation of pedi-
atric RCTs attributed only 25% (8 of 32) to slow recruitment.19,20
In our sample, slow recruitment was the main cause of early
discontinuation in 56% (15 of 32). The difference may stem
from the fact that the previous analysis was based on pub-
lished RCTs only. However, many discontinued RCTs are never
published or, if published, fail to acknowledge slow
recruitment.21 We addressed this limitation by evaluating REC
files and directly surveying trialists.
Our findings suggest that pediatric trials are at particu-
larly high risk for recruitment failure (40%), which is con-
cerning, especially because there are already many fewer
pediatric trials with major gaps in the RCT-informed clinical
evidence base.1 Nonetheless, our risk factor analysis should
prove encouraging to pediatric trialists, in that enrollment of
children is not an independent risk factor for slow recruit-
ment. Rather, recruitment in pediatric trials was associated with
the same risk factors as RCTs in adults. Nonindustry spon-
sorship may represent insufficient funding and lack of pro-
fessional planning and conduct, and acute care settings often
imply that substitute decision makers and caregivers are re-
luctant to make decisions about trial participation under time
pressure. The link between small sample size and recruit-
ment failure is less clear. Larger sample size might be a marker
for RCTs conducted in research networks or in more preva-
lent diseases. Those RCTs might be better organized from the
outset, and established networks around experienced investi-
gators might be better able to respond to recruitment chal-
lenges. Diseases in children often have a low prevalence and
thus may implicitly constitute a particular recruitment
challenge.
Our results support previous observations that pediatric
cancer trials seem to be less affected by recruitment problems.16
None of the 9 pediatric cancer trials in our sample was dis-
continued due to slow recruitment. The apparent success of
pediatric oncology trials may be the result of well-established
national and international networks, and integration of the
trial protocols into routine clinical care. Thus, investigators
designing trials for adult patients may consider the coopera-
tive research culture in pediatric oncology as a model.17,25
The next step may be careful estimation of the expected
recruitment performance, which is often overestimated.27,28
Unless reliable and easily applicable prediction models are
available,29 pilot trials that apply the full recruitment proto-
col are critical to test recruitment performance and identify
important barriers, such as lack of eligible patients, doubt
among recruiting physicians regarding equipoise, or complex
protocols.27 In our sample, only 7% of pediatric trial proto-
cols mentioned a feasibility study. Finally, active monitoring
of recruitment and proactive implementation of strategies to
bolster recruitment when necessary might be crucial once
RCTs are underway.30,31
More than one-third of pediatric RCTs were discontinued
prematurely, due primarily to slow recruitment. Investiga-
tors who plan to enroll children in an RCT should consider
measures to mitigate slow recruitment, especially if the trial
is conducted in the acute care setting, lacks industry partner-
ship, and has a small sample size. ■
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Pediatric, n (%) 33 (78) 53 (6) 5 (2) 23 (8) 5 (3) 5 (16) 15 (8)
Adult, n (%) 10 (22) 798 (94) 216 (97) 249 (92) 144 (97) 26 (84) 163 (92)
*In Zurich, we selectively included pediatric and surgical trials only.







Completed, n (%) 9 (100) 35 (73) 98 (84)
Discontinued due to slow recruitment, n (%) 0 13 (27) 19 (16)
*Same sample as used for multivariable regression; see Table IV.






Peer-reviewed journal, n (%) 46 (53) 484 (60)
Abstract/letter/other, n (%) 8 (9) 48 (6)
Not published, n (%) 32 (37) 276 (34)
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